DE69105323D1 - Bioelastomeres Arzneimittelabgabesystem. - Google Patents

Bioelastomeres Arzneimittelabgabesystem.

Info

Publication number
DE69105323D1
DE69105323D1 DE69105323T DE69105323T DE69105323D1 DE 69105323 D1 DE69105323 D1 DE 69105323D1 DE 69105323 T DE69105323 T DE 69105323T DE 69105323 T DE69105323 T DE 69105323T DE 69105323 D1 DE69105323 D1 DE 69105323D1
Authority
DE
Germany
Prior art keywords
polymer
physiological condition
functional group
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69105323T
Other languages
English (en)
Other versions
DE69105323T2 (de
Inventor
Dan W Urry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioelastics Research Ltd
Original Assignee
Bioelastics Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelastics Research Ltd filed Critical Bioelastics Research Ltd
Application granted granted Critical
Publication of DE69105323D1 publication Critical patent/DE69105323D1/de
Publication of DE69105323T2 publication Critical patent/DE69105323T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2045—Polyamides; Polyaminoacids, e.g. polylysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69105323T 1990-03-27 1991-03-26 Bioelastomeres Arzneimittelabgabesystem. Expired - Fee Related DE69105323T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49969790A 1990-03-27 1990-03-27

Publications (2)

Publication Number Publication Date
DE69105323D1 true DE69105323D1 (de) 1995-01-12
DE69105323T2 DE69105323T2 (de) 1995-06-01

Family

ID=23986317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69105323T Expired - Fee Related DE69105323T2 (de) 1990-03-27 1991-03-26 Bioelastomeres Arzneimittelabgabesystem.

Country Status (6)

Country Link
US (1) US6328996B1 (de)
EP (1) EP0449592B1 (de)
JP (1) JPH0729942B2 (de)
AT (1) ATE114458T1 (de)
DE (1) DE69105323T2 (de)
ES (1) ES2067150T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727639B2 (en) * 1996-11-27 2000-12-21 Gunther Beisel Composition for producing a long-lasting satiation effect
GB9718463D0 (en) * 1997-08-29 1997-11-05 Dynal As Biomolecules
JP2002507437A (ja) * 1998-02-27 2002-03-12 バイオエラスチックス・リサーチ・リミテッド 組織の増強及び回復のための注射可能インプラント
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
CA2457564C (en) 2001-10-05 2009-04-07 Surmodics, Inc. Particle immobilized coatings and uses thereof
AU2003212955A1 (en) * 2002-02-07 2003-09-02 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
GB0412631D0 (en) * 2004-06-07 2004-07-07 Cambridge Applied Polymers Ltd Polymer release system
EP1812480A4 (de) * 2004-10-14 2010-11-03 Tufts College Elektrochemisch abbaubare polymere
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
CN101500606B (zh) * 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递系统
US20130172274A1 (en) * 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101384272B (zh) * 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US20090098110A1 (en) * 2007-05-30 2009-04-16 Duke University Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
PT2464370T (pt) 2009-08-14 2017-05-17 Phasebio Pharmaceuticals Inc Péptidos vasoativos intestinais modificados
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
EP3424948B1 (de) * 2016-04-07 2021-07-28 Industry-University Cooperation Foundation Hanyang University ERICA Campus Gegen vaskulären endothelialen wachstumsfaktor gerichtetes fusionspolypeptid mit peptid-elastin und selbstanordnende nanostruktur zur hemmung der angiogenese

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867520A (en) * 1971-04-14 1975-02-18 Ajinomoto Kk Medicated polyamino acid film for occlusive dressing therapy
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
FR2353282A1 (fr) * 1976-06-02 1977-12-30 Invap Etablissement Application de l'elastine et de ses derives en cosmetique
US4187852A (en) * 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
DE3104815C2 (de) * 1980-02-13 1983-07-07 Japan Atomic Energy Research Institute, Tokyo Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) * 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4605413A (en) 1983-09-19 1986-08-12 The University Of Alabama At Birmingham Stimulation of chemotaxis by chemotactic peptides
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4693718A (en) * 1985-10-31 1987-09-15 University Of Alabama In Birmingham Stimulation of chemotaxis by chemotactic peptides
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
EP0349428B1 (de) * 1988-06-30 1993-01-20 Centre National De La Recherche Scientifique (Cnrs) Verfahren zur Herstellung von kolloidalen dispergierbaren Proteinsystemen, wie Nanopartikeln

Also Published As

Publication number Publication date
DE69105323T2 (de) 1995-06-01
ES2067150T3 (es) 1995-03-16
EP0449592B1 (de) 1994-11-30
JPH0729942B2 (ja) 1995-04-05
ATE114458T1 (de) 1994-12-15
EP0449592A1 (de) 1991-10-02
US6328996B1 (en) 2001-12-11
JPH04221323A (ja) 1992-08-11

Similar Documents

Publication Publication Date Title
DE69105323D1 (de) Bioelastomeres Arzneimittelabgabesystem.
ATE122879T1 (de) Verabreichungsformen für pharmaka.
NO912769D0 (no) Avleveringssystem for medikamenter.
ATE434423T1 (de) Medikamentenfreisetzender stent
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
EP1234586A3 (de) Selektiv auf der Leber wierkenden Pharmaka
NO872381D0 (no) Fremgangsmaate for fremstilling av langsomt frigivende preparater.
NO884474L (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
DE3884314D1 (de) Polymermischung mit umkehrphasen Morphologie zur kontrollierten Wirkstoffabgabe.
DE3783257D1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
DE3774889D1 (de) Theophyllintablette mit verzoegerter freigabe.
GR3029496T3 (en) Implantable moulded body for administering active substances to plants
ATE54824T1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
JPS6456055A (en) Medical molded article composed of lactic acid/epsilon-caprolactone copolymer and its preparation
NO983917L (no) Anvendelse av IL-7 for behandling av autoimmune sykdommer og sµrlig insulinavhengig diabetes mellitus
Noble Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility.
DE69123344D1 (de) Künstliches blutgefäss sowie herstellung desselben
ATE96025T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
Soheir Experimental trials in treatment of chronic Salmonellosis and carrier state with bilharzial infection
Rozkin et al. Comparative study of the anticoagulant activity of sulfated polysaccharides from marine brown algae
Frick Prophylactic use of antibiotics against postoperative infections in reconstructive vascular surgery with alloplastic material.
SE8204283L (sv) Polypeptid-mellanprodukt for framstellning av en polypeptid-slutprodukt och dess farmaceutiskt acceptabla salter med biologisk formaga att inducera utveckling av t-lymfocyter men inte av komplementreceptor (cr?72+) b...
ATE105196T1 (de) Nadelloses einweg-injektionssystem.
KR930700109A (ko) 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘
RU93033753A (ru) Способ получения медицинской повязки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee